When Dylan Jovine releases a new biotech, it pays to act fast...
A note from the Editor: Market Makers Journal is dedicated to providing readers like you with unique opportunities. The message below from one of our business associates is one we believe you should take a serious look at.
When Dylan Jovine releases a new biotech, it pays to act fast. Immunogen was taken over 33 days after he said it would for a 463% gain... We just sold Viking Therapeutics for a 273% gain... He sold Chemocentryx for a 300% gain... And, today I have some great news: He just released his #1 Biotech for April. I urge you to get the details on his latest pick before it's too late. You'll discover: 1. How a $4 micro-cap beat the odds to win an FDA approval on a new kind of "Smart Chemo" that's like a heat-seeking missile against cancer. 2. Why the Journal Nature is calling it, "The Dawn of a New Era Against Cancer." 3. Why Big Pharma giants Pfizer, AbbVie, Merck and Johnson & Johnson put $60 billion into this treatment within the past 12 months. Get the name of the stock here >>> Never before has so much money invested in a new cancer treatment so quickly. Morgan Stanley estimates the market is worth at least $140 billion. But right now, its stock price is just a tiny fraction of that size. See why this $4 "Smart Chemo" stock can soar 300% (or more) >>> All the best, Simmy Adelman, Publisher Behind the Markets
